ENTA - Enanta Year-over-year net earnings per share growth for the last 12 months

enanta.com - graphic logo of issuer ENTA

Diversification of antiviral development and royalties minimize R&D risks, allowing Enanta Pharmaceuticals (ENTA) to confidently withstand competition in clinical trials. The quarterly EPS dynamics on the GURU.Markets chart currently stands at 21.20, confirming this momentum. The implementation of zero-waste cycles and strict environmental control of chemical production complete the picture.

enanta.com (ENTA) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Enanta Pharmaceuticals (ENTA)

- market value and analyst target forecast:
Initial company analysis:Enanta Pharmaceuticals
Manufactured product of Enanta Pharmaceuticals, Inc

This indicator measures the dynamics of earnings per share, reflecting management's ability to control operating expenses under inflationary pressure. Steady growth in this metric serves as a stress-testing tool for business resilience against rising resource costs. By analyzing the quarterly EPS growth rate, investors assess real margins following the publication of 10-Q reports. For Enanta Pharmaceuticals (ENTA), this confirms the effectiveness of commercializing innovative small-molecule platforms. The brand's high scientific authority translates into financial efficiency in drug development.

Key competitors

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|IVVD (Invivyd Inc) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)